One of the major obstacles in allogeneic bone marrow transplantation (allo-BMT) is prolonged T cell dysfunction resulting in a variety of infectious complications in the months to years after hematologic engraftment. We previously showed that immobilized extracellular matrix (ECM) proteins such as fibronectin (FN), the CS-1 domain of FN, or collagen (CO) acted synergistically with immobilized anti-CD3 to induce T cell proliferation. In addition, the comitogenic effect of ECMs could be mimicked by immobilized mAb reactive with a common beta 1 chain (CD29) of very late activating (VLA) antigens which include ECM receptors. Since the interaction of T cells with ECMs appears to play an important role in the process of T cell reconstitution following allo-BMT, we examined the expression of VLA antigens (alpha 1-alpha 6, beta 1) and their functional roles in CD3-mediated T cell proliferation at various times after T cell depleted allo-BMT. VLA beta 1 as well as VLA alpha 4, alpha 5, and alpha 6 expression was lower than normal controls during the first 3 mo after allo-BMT and auto-BMT, whereas these expressions returned to normal levels by 4 mo after allo-BMT and auto-BMT. Although alpha 1 and alpha 2 were not expressed on lymphocytes from normal controls, these antigens were expressed on lymphocytes at the detectable levels (5-15%) from patients after allo-BMT and auto-BMT. VLAcr4, a5, and a6 expression was lower than normal controls during the first 3 mo after allo-BMT and auto-BMT, whereas these expressions returned to normal levels by 4 mo after allo-BMT and auto-BMT. Although cal and a2 were not expressed on lymphocytes from normal controls, these antigens were expressed on lymphocytes at the detectable levels (5-15%) from patients after allo-BMT and auto-BMT. Both CD29 and CD3 were expressed at normal levels on lymphocytes from patients >3 mo after allo-BMT, whereas T cell interaction with ECM through VLA proteins or crosslinking of VLAfl1 expressed by T cells with anti-CD29 mAb results in poor induction of CD3-mediated T cell proliferation for a prolonged period (>1 yr) after allo-BMT. In contrast, T cell proliferation induced by crosslinking of anti-CD2 or anti-CD26 with anti-CD3 was almost fully recovered by 1 yr post-allo-BMT. After autologous BMT, impaired VLAmediated T cell proliferation via the CD3 pathway after auto-BMT returned to normal levels within 1 yr despite no significant difference in CD3 and CD29 expression following either allo-or auto-BMT. The adhesion of T cells from post- 
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Introduction
Allogeneic bone marrow transplantation (allo-BMT)' has been shown to provide potentially curative therapy for patients with a variety of diseases including many hematologic malignancies (1, 2) . However, one of the major obstacles in allo-BMT is prolonged T cell dysfunction resulting in a variety of infectious complications in the months to years after hematological engraftment (3) (4) (5) . Previous studies have documented a variety of in vitro T cell dysfunctions after allo-BMT, including impaired ability to provide help to B cell immunoglobulin synthesis, poor proliferative response to mitogenic stimuli, and abnormal function of cytotoxic effector cells (6) (7) (8) (9) (10) . Moreover, these impaired in vitro T cell functions have been shown to continue for several years (8, 10) , suggesting that these T cell dysfunction(s), as yet uncharacterized, may contribute to increased susceptibility to opportunistic infections.
Adhesion molecules on T cells have attracted increasing attention because of the diverse roles that these structures play in many vital cell functions including differentiation, recirculation, antigen recognition, activation, and proliferation (11, 12) . Based on their biochemical structure, lymphocyte adhesion molecules have been classified into three broad categories: the immunoglobulin, integrin, and selectin families (11) . The very late activating (VLA) antigens constitute the,6/1 integrin subfamily (13) , and are one of the major adhesion receptors expressed by T cells. They are transmembrane glycoproteins consisting of a common /I1 subunit (CD29) nonconvalently associated with distinct a chains to form different heterodimers (12) . The VLA proteins function as cell surface receptors mediating cell-cell and cell-extracellular matrix protein (ECM) adhesive interactions. Recent studies have clearly shown that the VLA molecules not only mediate T cell adhesion, but can synergize with the CD3/TCR pathway to promote T cell proliferation (14) (15) (16) (17) (18) (19) . Coimmobilization of ligand proteins of the VLA receptor family and submitogenic doses of anti-CD3 result in strong T cell proliferation through at least five receptor/ligand interactions: VLA-3/collagen, VLA-4/CS 1 region of fibronectin (EN), VLA-4/VCAM-1, VLA-5/RGD sequence of FN, and VLA-6/laminin. This comitogenic effect of ECM can be mimicked by immobilized mAb (anti-4B4) reactive with a common /il chain (CD29) (20) . Moreover, we showed that the engagement of VLA molecules by specific antibodies or by their ligands rapidly stimulated tyrosine phosphorylation on a 105-kD protein (pplO5) in T cells (21) . Furthermore, it has been proposed that the interaction of CD4-CD8-(double negative) immature thymocytes with FN expressed on thymic stromal cells via the VLA-4 and VLA-5 receptors plays a crucial role in the differentiation of thymocytes (22, 23) . The interactions of T cells with ECM thus could play an important role in normal T cell differentiation and may also play an important role in the process of T cell reconstitution after BMT.
In this paper, we examined the expression of VLA antigens (al -a6, /1) and their functional roles in CD3-mediated T cell proliferation at various times after T cell-depleted allo-BMT, to determine whether VLA molecules are involved in prolonged T cell dysfunction after allo-BMT. We found T cell interactions with ECM through VLA proteins or crosslinking of VLA /31 with anti-CD29 mAb result in poor induction of CD3-mediated T cell proliferation for a prolonged period (> 1 yr) after allo-BMT despite almost normal CD3 and CD29 expression. This prolonged impaired function of VLA antigens appears to be due to some other defects in the process of VLA-mediated signal transduction, since the adhesion of T cells from post allo-BMT patients to FN-coated plates was normal or increased and the induction of tyrosine phosphorylation of pplO5 was not impaired. Thus, abnormal VLA function could explain, at least in part, the persistent immunodeficient state after T cell-depleted allo-BMT and may be involved in susceptibility to opportunistic infections in such patients.
Methods
Patients and samples. This study is based on the analysis of 38 patients who underwent allo-BMT over a 4-yr period at Dana-Farber Cancer Institute (DFCI). 16 Further removal of monocytes was achieved by incubation with 5 mM L-leucine methyl ester HC1 as described (14, 15) . The lymphocyte populations thus obtained were cultured at 37°C in triplicate wells at a concentration of 10' cells/well in a serum-free medium consisting of Iscove's MEM supplemented with 0.1% BSA, 30 /Ag/ml human transferrin, 10 ug/ml soybean lipids, 50 jsg/ml cholesterol, 4 mM L-glutamine, 25 mM Hepes buffer (Microbiological Assoc. Inc., Rockville, MD), 0.5% sodium bicarbonate, and 50 ,g/ml gentamicin sulfate (Schering, Kenilworth, NJ) as described (14, 15 Cell adhesion assays. Cell adhesion assays were performed as described previously (18) . In brief, 96-well microtiter plates were incubated with 100 ,il of FN (10 jig/ml in PBS) for 3 h at room temperature, followed by incubation with heat-treated (10 min at 80°C) BSA (5 'sg/ ml in PBS) for 2 h and washing with PBS. Plates coated with heattreated BSA alone were also prepared for controls. The lymphocyte population depleted of monocytes obtained as described in proliferation assays was labeled with [51Cr]sodium chromate (New England Nuclear, Boston, MA) for 1 h before adhesion assays, and then plated in triplicate on FN-coated plates and BSA alone-coated plates, and incubated for 1 h at 37°C. The unbound cells were removed by gentle washing with PBS. The bound cells were lysed with 1% Nonidet P40, and the cell lysates was analyzed using a y scintillation counter. The percent specific binding was calculated as follows: [(cpm of FN-coated plate)/cpm of BSA alone-coated plate)/cpm of total cells plated] X 100.
Tyrosine phosphorylation studies. The monocyte-depleted lymphocyte populations obtained from three patients 6 mo after allo-BMT and a normal volunteer were analyzed. The cells (5 x 106 cells/i mi/sample) were resuspended in Iscove's serum-free media, and either left as controls or incubated with anti-CD29 mAb (10 jsg/ml) for 15 min at 4°C.
After washing once with cold media, the cells were incubated with 482 Sugita et al. 200 ,ll of media containing 10 pug/ml rabbit anti-mouse IgG (Jackson ImmunoResearch Labs, West Grove, PA) for 15 min at 370C. The reactions were terminated by the addition of 5 ml of stop solution (cold PBS containing 10 mM NaF and 1 mM Na vanadate), and then solubilized in lysis buffer (50 mM Tris-HCI, pH 8.0 containing 1% NP-40, 150 mM NaCl, 5 mM EDTA, 1 mM PMSF, 10 mM iodoacetamide, 10 mM NaF, 1 mM Na vanadate) for 15 min on ice. The cell lysates were separated on a 7.5% SDS-polyacrylamide gel under reducing conditions, and then transferred to nitrocellulose membrane, and blotted using "nI-labeled anti-phosphotyrosine mAb described previously (21 
Results
Expression of VIA antigens on lymphocytes post allo-BMT. To determine the functional properties of VLA proteins on lymphocytes post-T cell-depleted allo-BMT, we first examined the expression (% positive cells) of VLA proteins comprising of distinct a chains (al -a6) and a,/I chain (CD29). As summarized in Fig. 1, A Fig. 2 , expression of VLA /1 integrin on lymphocytes from a normal control was found as two peaks representing low and high density expression, while only one high peak was seen on lymphocytes from patients at any time points up to 1 yr post-allo-BMT. Thereafter, two peaks representing a relatively small density difference (moderate to high) reappeared. Impaired comitogenic effect of solid phase-immobilized anti-CD29 mAb on CD3-dependent T cell proliferation postallo-BMT. In our earlier studies, we showed that VLA antigens not only mediate cell adhesion, but can synergize with the CD3 pathway to promote T cell proliferation (14, 15, 18, 20) . As shown in Fig. 3 A, in a normal control anti-CD29 as well as other antibodies alone could not induce significant levels of T cell proliferation above background (< 1,000 cpm). In addition anti-CD3 alone could only induce minimal T cell proliferation. However, coimmobilization of anti-CD3 with anti-CD29 induced marked T cell proliferation. Anti-CD3 plus anti-CD2 or anti-CD26 also induced marked T cell proliferation as previously reported (31) . In contrast, anti-L-selectin, which identifies a member of different class of adhesion molecule (1 1, 29), had virtually no comitogenic effect with anti-CD3. Since CD29 expression on lymphocytes from post-allo-BMT patients is higher than in normal controls, it was expected that comitogenic effect of anti-CD29 via the CD3 pathway might be stronger in post-allo-BMT lymphocytes than in normal control lymphocytes. However, as shown in Fig. 3 Samples obtained from patients after allo-BMT (n = 60), after auto-BMT (n = 25), and healthy volunteers (n = 30) were analyzed as described in Fig. 2 Fig. 4 , this impaired T cell proliferation recovered within 1 yr in patients after auto-BMT, it lasted for more than 2 yr in patients after allo-BMT. Impaired comitogenic effect of solid-phase immobilized ECM on CD3-dependent T cell proliferation post-allo-BMT. As we reported previously (14, 20) , ligation of anti-CD29 appears to mimic interaction between extracellular matrix proteins and VLA antigens expressed on T cells and coimmobilization of ECM with anti-CD3 can result in T cell proliferation. As shown in Fig. 5 A, in a normal control, neither anti-CD3 alone nor ECM such as CO, LN, and FN alone, resulted in minimal T cell proliferation. However, coimmobilization of anti-CD3 with ECMs induced marked T cell proliferation in a dose-dependent fashion. In contrast, as expected from the results of Fig. 3 B, an impaired CD3: ECM-mediated T cell proliferation was also observed in a representative patient 9 mo after T cell depleted allo-BMT (Fig. 5 B) . The defect of costimulation by coimmobilization of anti-CD3 mAb and ECMs were observed even in the higher doses of ECMs (10 and 25 pg/ml: data not shown). Fig. 6 summarizes the results of T cell proliferation studies obtained from normal controls, T cell-depleted allo-and auto-BMT patients. As shown in Fig. 6 , this impairment as in the case of costimulation by coimmobilization of anti-CD3 and anti-CD29 mAbs, also lasted longer in patients after allo-BMT than after auto-BMT. Of interest, when different ECMs were examined, CD3:LN-mediated T cell proliferation recovered earlier than CD3:CO or CD3:FN mediated T cell proliferation in both patient populations.
Normal or increased adhesion of lymphocytes to FN after allo-BMT. Prolonged impaired VLA-mediated T cell costimulation via the CD3 pathway after allo-BMT appears to be due to either lowered avidity between VLA proteins and ECM, or some defects in the process of signal transduction through VLA proteins on T cells. Since the majority of T lymphocytes prefer- entially express FN receptors (VLA-4 and VLA-5), we examined the binding of lymphocytes to fibronectin-coated plates using 51Cr-labeled lymphocytes from normal controls and patients 4-12 mo after T cell-depleted allo-BMT. As shown in Fig. 7 , the specific binding of lymphocytes to fibronectin in normal controls (n = 5) was 7.4 ±0.8%, compared to 9.8 ±3.5% in patients after allo-BMT (n = 5 (21) . Since tyrosine phosphorylation on cellular proteins is an early and obligatory event in the activation of T cells (32) (33) (34) (35) (36) (37) this phosphorylation event may play a role in the transduction of activation signals through this molecule. Therefore, we next attempted to determine whether a pplOS tyrosine phosphorylation was observed in lymphocytes obtained from a normal control and three patients 6 mo following T cell-depleted allo-BMT. For this purpose, the crosslinking of VLA /81 (CD29) with a specific mAb (anti-4B4) was used to induce the pplOS, and anti-phosphotyrosine mAb was used to detect this molecule. As shown in Fig. 8 , densitometric analysis showed that increased pplO5 was observed in all three patients studied compared to that observed in the normal control. It should be noted that in addition to pplOS tyrosine phosphorylated protein, an approximately 120-kD protein is also tyrosine phosphorylated that is less markedly induced in both normal lymphocytes and patients' lymphocytes. Our results indicate that tyrosine phos- phorylation of a 105-and 120-kD protein is not impaired in lymphocytes after allo-BMT, suggesting that other defects in VLA-mediated signals may be present in such patients.
Discussion
In this study, we showed that T cells obtained from post T celldepleted allo-BMT patients exhibited decreased proliferative response triggered by immobilized anti-CD3 plus ECMs or anti-CD29 mAb compared with T cells from normal controls. Such impaired VLA-mediated costimulation persisted for a prolonged period (more than 2 yr) after T cell depleted allogeneic BMT.
In contrast, T cells from auto-BMT patients initially showed low response, but later gained normal levels of proliferation within 1 yr after transplantation. Previous studies of immune function after allogeneic BMT have documented a variety of in vitro T cell abnormalities after engraftment (6) (7) (8) (9) (10) . More recently we evaluated cells from patients without GVHD who have received donor marrow depleted of CD6+ T lymphocytes (24) and reported that stimulation by either nonspecific lectin (PHA) or antibodies to CD2 (anti-Ti 12 + anti-Ti 13) resulted in decreased levels of T cell proliferation compared with controls for over 12 mo after BMT. Lum and colleagues (38) reported that the signal transduction response mediated by the CD3-antigen receptor as measured by calcium flux is defective early after both autologous and allogeneic BMT and such defective anti-CD3 induced calcium flux returned to the almost normal levels after 1 yr post-BMT. Thus, the CD3 pathway for activating T cells appears to be generally disturbed both in allo-and auto-BMT patients in a relatively early phase of post-BMT.
It is not conclusive at present whether the prolonged VLAmediated signaling defect in T cells observed after T cell depleted allo-BMT can be generalized to all allo-BMT because there remains the possibility that the difference in VLA function between T cell depleted allo-and auto-BMT comes from the difference between absence and presence of mature T cells included in marrow grafts, but not from the difference between allo-and auto-BMT. However, the above possibility appears to be less likely for the following reasons. Compared with the findings of other studies characterizing immune reconstitution after allogeneic transplantation with non-T cell-depleted marrow grafts (39), we observed no significant delay in the recovery of normal numbers of T lymphocytes in our patients (24). The numbers of CD3 + T cells increase gradually after BMT, becoming the predominant lymphoid population by 6 wk and reaching control levels after 10 to 12 wk (24). Moreover, our recent studies of phenotypic comparison between T cell-depleted allogeneic BMT patients and auto-BMT patients showed that there are virtually no significant differences in T cell subsets between these groups but inverted CD4/CD8 ratio was continuously observed in both groups over 2 yr which is in contrast to the CD4/ CD8 ratio of normal individuals (40) . Moreover, as shown in Fig. 1, A and B , there are no significant differences of the expression of VLA-,3 chain and VLA-a chains on lymphocytes from T cell-depleted allo-BMT and auto-BMT patients' group. Others reported that although the recovery of various T cell proliferative responses were more delayed in recipients of T cell-depleted marrow grafts, compared to non-purged allo-BMT patients, auto-BMT and normal controls, there are no significant differences in such T cell responses after one year between these groups (39) . Moreover, as shown in our results, T cell costimulation by CD2 or CD26 molecule via the CD3 pathway was rapidly improved and almost reached normal levels by 1 yr both in our T cell purged allo-BMT and auto-BMT patients. However, the prolonged impairment of the VLA-mediated costimulation via the CD3 pathway was still specifically observed in our T cell purged allo-BMT patients. Taken together, these results strongly suggest that the prolonged impairment of the VLA mediated T cell costimulation post-allo-BMT appears to come from insufficient education of donor's lymphoid stem cells in recipient thymus and/or thymus equivalent. Further intensive studies comparing VLA-mediating signaling events between T cell-depleted and non-T cell-depleted allo-BMT will be required to clarify whether our finding is common to all allo-BMT patients.
The reaction of specific peptide antigen or antibodies against the antigen specific T cell receptor (TcR)/CD3 complex is generally unable to induce T cell proliferation and lymphokine secretion on its own (41) . Rather, T cells require a second signal, which is referred to as costimulation, and this activity can be provided by a number of accessory molecules expressed on the T cell surface such as CD28, LFA1, CD29/VLA, and CD26 (14, 21, 31, (42) (43) (44) (45) . Although physiological meaning of redundancy of costimulatory molecules is not fully understood, it has been speculated that T cells might use different sets of these molecules dependent upon their functional subsets, opposing cells with which they interact, or places they must be activated. Our observation that defective costimulation of T cells was relatively restricted to VLA-mediated pathway in the late phase of T cell-depleted allo-BMT further support the differential regulation of T cell costimulation. Immunodeficiency after autologous BMT is generally regarded to be less and milder compared to that after allo-BMT (1, 2, 46) . Especially, cytomegalovirus infections are much less common after autologous or syngeneic BMT than after allo-BMT (46) . There may be a possibility that the prolonged impairment of VLA-mediated T cell proliferation after T cell-depleted allo-BMT may reflect at least in part, the immunoincompetent status found in such patients.
What are mechanisms for the defective T cell costimulation by very late activation (VLA) antigens? In both T cell-depleted allo-BMT and auto-BMT patients, percentages of expression of VLA P1, as well as VLA a4, a5, and a6 were lower than those in normal controls during the first 3 mo after BMT, but they returned to normal range by 4 mo. In addition, mean density of VLA P1 was found to be significantly higher on T cells from patients at any time points after BMT. Moreover, patients' T cells normally or rather more strongly adhered to ECM-coated plates even late period of post-BMT. Thus, impairment of VLA-mediated costimulation can not be attributed to poor expression or poor binding capacity of VLAs. Defective site, if any, may be located in the signaling pathway after an event in which VLAs interacted with their ligands. The reason why the CD3:laminin induced T cell costimulation recovers relatively faster than other CD3:ECMs induced T cell proliferation in allo-BMT patients is not clear at present. Since it is reported that there are many ill-characterized laminin receptors in addition to the integrin family of antigens (47) , it may be possible that signal inducing capacity of VLA-unrelated laminin receptors on T cells may recover faster than that of VLA-receptors.
Although T cell-depleted allo-BMT is a model to study recapitulation of T cell ontogeny in adults, relative T cell immuno-incompetence of human neonates appears to be somewhat different from the T cell immuno-incompetence of T celldepleted allo-BMT. Because we recently showed that in both T cell-depleted allo-BMT and auto-BMT patients, CD4 + CD45RA+ naive, and CD4 + CD29+ memory T cells were markedly decreased during the first 24 mo after BMT (40) , whereas in neonates, their T cells include few CD29 memory T cells and consist almost exclusively of the CD45RA naive T cells (48) .
Recent studies have documented that tyrosine phosphorylation on cellular proteins is an early and obligatory event in the activation of T cells (32) (33) (34) (35) (36) (37) . More recently, we showed that engagement of VLA molecules by specific antibodies or by their ligands rapidly stimulated tyrosine phosphorylation of a 1 05-kD protein in T cells (21) . Tyrosine phosphorylation events triggered via VLAs have also been described in KB carcinoma cells and NIH 3T3 fibroblasts. Cross-linking of VLA-3 in KB cells leads to tyrosine phosphorylation of proteins of 120 kD, and adhesion and spreading on fibronectin or on anti-,31 antibodies leads to rapid tyrosine phosphorylation of a protein of similar size (49, 50) . More recently, it was demonstrated that these proteins are identical to ppl25FAK, a structurally distinct protein-tyrosine kinase associated with focal adhesion (51). Our preliminary results showed that pplO5 is not the same protein as ppl 25FAK (our unpublished data by Y. Nojima et al.) . It is likely that pplO5-125FAK may be components of signal transduction pathway responsible for the transmission of signals from the cell surface integrins into the cell. Normal or even enhanced tyrosine phosphorylation of pplO5-120 in T cells from allo-BMT patients which are defective in proliferative response stimulated with anti-CD3 plus ECMs or anti-CD29 were well correlated with the normal or enhanced binding capacity of these T cells to FN-coated plates, implying that the impaired costimulation by VLAs is not attributed to this biochemical event. Although it is not clear whether tyrosine kinase activation event is actually involved in the comitogenic proliferative signals after the engagement of the VLA molecules, our data suggest that there are some other defects in the process of VLA-mediated signal transduction in the downstream of pplO5.
Further studies will be undertaken to determine the precise molecular defect of VLA-mediated T cell costimulatory activity which was specifically observed in allo-BMT patients.
